Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20001742 | 0.85 | ALDH1A1 (0.43) | KDM4ENPC1RAB9AKMT2ASIGMAR1 | |
| SCHEMBL13495377 | 0.83 | GAA (0.42) | L3MBTL1NPC1RAB9ASIGMAR1HTT | |
| SCHEMBL22386345 | 0.82 | ABCB11 (0.44) | NPC1LMNARAB9ASIGMAR1NOTUM | |
| SCHEMBL20001754 | 0.80 | RXRA (0.44) | L3MBTL1SIGMAR1NOTUMPOLBCACNA2D1 | |
| SCHEMBL15412955 | 0.77 | RXRA (0.43) | LMNAKMT2ASIGMAR1PTGS2HTT | |
| SCHEMBL29373325 | 0.74 | L3MBTL1 (0.43) | KDM4EL3MBTL1NPC1LMNARAB9A | |
| SCHEMBL15412952 | 0.72 | NR3C1 (0.44) | L3MBTL1NPC1LMNARAB9AKMT2A | |
| SCHEMBL18504845 | 0.72 | GABRA1 (0.45) | KMT2ASIGMAR1NOTUMHTT | |
| SCHEMBL15754826 | 0.71 | NPC1 (0.60) | KDM4EL3MBTL1NPC1LMNARAB9A | |
| SCHEMBL5539090 | 0.71 | HTT (0.56) | KDM4EL3MBTL1NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | KDM4E 2293/4885L3MBTL1 2878/4885NPC1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.